The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | DALY 2-EU crossover analysis: zamto-cel shows promise in older patients with R/R LBCL
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a crossover analysis from the randomized DALY 2-EU trial (NCT04844866) evaluating zamtocabtagene autoleucel (zamto-cel), a dual CD19/CD20 CAR T-cell therapy, in older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) ineligible for autologous stem cell transplantation. Dr Shah highlights that zamto-cel demonstrated superior outcomes to R-GemOx in the second-line setting. Patients who crossed over to zamto-cel after progression on R-GemOx achieved outcomes comparable with those treated with zamto-cel earlier. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
